Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients

Table 3 Resistance-associated substitution results in 14 patients with virological treatment failure for whom sequencing was performed in routine care

Pat	HCV treatment history	Treatment received	HCV genotype		Cirrhosis	ARV treatment	RAS
			Before treatment	After treatment			NS3	NS5A	NS5B
A	Pretreated	SOF + SMV 12 wk	1a	1a	Yes	II	Q80K, I170T, S174N	Abs	Abs
B	Pretreated	SOF + SMV 12 wk	1a	1a	Yes	II	D168V	Abs	Abs
C	Pretreated	SOF/LDV 12 wk	4	4a	No	PI	Abs	Abs	Abs
G	Pretreated	SOF/LDV + RBV 12 wk	4	4d	No	Others	Abs	Abs	Abs
H	Pretreated	SOF + DCV 10 wk3	4	4	No	Others	Abs	ND	Abs
I	Naive	SOF/LDV 12 wk	1a	1a	No	PI	Abs	Abs	Abs
J	Pretreated	SOF/LDV 12 wk	1a	1a	No	Others	ND	Y93C	Abs
L	Naive	SOF + DCV 13 wk2	1a	1a	Yes	NNRTI	Q80K	Abs	Abs
M	Pretreated	SOF/LDV 12 wk	4	4a	No	PI	ND	Abs	A421V, M414L
N	Pretreated	SOF/LDV + RBV 12 wk	1a	1a	Yes	II	A168V	30E, 58D	Abs
P	Pretreated	SOF + DCV + RBV 12 wk1	1a	1a	No	PI	Abs	Y93N	Abs
Q	Pretreated	SOF + DCV + RBV 24 wk1	1a	1a	No	Others	T54S	Q30R	Abs
R	Pretreated	SOF + DCV 24 wk2	1a	1a	Yes	II	Q80K	Y93C	Y448H
W	Pretreated	SOF + DCV 24 wk1	1	1a	Yes	II	Abs	Q30H	Abs

¹Initial dose of DCV: 30 mg/d;

²Initial dose of DCV: 60 mg/d;

³Initial dose of DCV: 90 mg/d. Pat: Patient; ARV: Antiretroviral; RAS: Resistance-associated substitution; NS3: Non-structural-3; NS5A: Non-structural-5A; NS5B: Non-structural-5B; SOF: Sofosbuvir; RBV: Ribavirin; DCV: Daclatasvir; LDV: Ledipasvir; SMV: Simeprevir; ND: Not done; PI: Protease inhibitor; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; II: Integrase inhibitor; Abs: No RAS found.